Žaliūnas, Remigijus

The proposal presents a pioneering research initiative aimed at enhancing the diagnosis and understanding of Coronary Microvascular Dysfunction (CMD) through the identification of novel blood-based biomarkers. This endeavor is particularly focused on patients exhibiting stable angina or non-obstructive Coronary Artery Disease (CAD), as well as those recovering from ST-Elevation Myocardial Infarction (STEMI), thereby addressing a significant gap in current cardiovascular disease management and treatment strategies. Central to the proposal is the innovative approach of leveraging advanced diagnostic techniques and cutting-edge biomarker research to pinpoint specific indicators that could revolutionize the way CMD is identified and treated. By focusing on a cohort of patients who traditionally present with ambiguous symptoms and often receive delayed or inaccurate diagnoses, the project aims to bring about a paradigm shift in the early detection and personalized treatment of heart disease. A key feature of this research initiative is the collaboration between leading medical research institutions in Lithuania and Poland, which facilitates the creation of a comprehensive and diverse patient dataset. This cross-border partnership not only enriches the study with a wide range of genetic and lifestyle backgrounds but also strengthens the scientific validity and potential impact of the findings on a broader European and global scale. The methodology outlined in the proposal is meticulously designed to encompass both invasive and non-invasive diagnostic tools for assessing CMD, thereby offering a holistic view of the disease's manifestations. Invasive procedures, such as coronary angiography, are complemented by state-of-the-art non-invasive techniques, including advanced imaging and stress tests, ensuring a thorough evaluation of microvascular function. At the heart of the research is the biomarker analysis, which involves the detailed examination of patient blood samples to identify specific molecular or genetic markers indicative of CMD. This analysis is supported by sophisticated analytical techniques and bioinformatics tools, enabling the researchers to sift through vast amounts of data to uncover potential biomarkers with clinical relevance. Furthermore, the proposal highlights the application of machine learning algorithms to develop predictive models based on the identified biomarkers. These models aim to accurately predict the presence and severity of CMD, offering a powerful tool for clinicians in the diagnosis and personalized treatment planning for patients. This integration of machine learning with biomarker research represents a cutting-edge approach to cardiovascular medicine, promising to enhance the precision and effectiveness of CMD management. The project's implications for patient care and the broader field of cardiology are profound. By enabling the early detection and tailored treatment of CMD, the research has the potential to significantly improve patient outcomes, reduce the burden of heart disease, and pave the way for a new era of precision medicine in cardiovascular care. The proposal underscores the commitment to innovation, collaboration, and the advancement of healthcare, setting a new standard for research excellence and patient-centered care in the fight against heart disease. In summary, this proposal outlines a comprehensive and innovative research project aimed at transforming the diagnosis and treatment of Coronary Microvascular Dysfunction through the discovery of blood-based biomarkers. Through a collaborative effort between Lithuanian and Polish institutions, the use of advanced diagnostic methodologies, and the application of machine learning for predictive modeling, this project stands to make a significant contribution to the field of cardiology and the well-being of patients worldwide.